Sleep Disorder Testing - Mayo Clinic Laboratories
Determining orexin-A/ hypocretin-1 levels through CSF testing provides a sensitive and specific result to guide appropriate treatment for patients.
Innovative Alzheimer's disease diagnostic tool unveiled - Insights
Mayo Clinic Laboratories has marked a significant advancement in the fight against Alzheimer's disease with the introduction of an innovative diagnostic test. This noninvasive blood test accurately detects the p-Tau217 biomarker, indicative...
Mayo Clinic Infectious Disease Study Noted in Clinical Microbiology Newsletter - Insights
An article recently published in the Clinical Microbiology Newsletter made mention of a Mayo Clinic study. The article discussed a topic that has become increasingly popular—self-collected specimens.
Mayo Clinic Laboratory and Pathology Research Roundup: June 26 - Insights
This week’s Research Roundup highlights expanded phenotypes and outcomes among 256 LGI1/CASPR2-IgG positive patients.
Mayo Clinic Laboratory and pathology research roundup: March 7 - Insights
This week's Research Roundup features: Membranous nephropathy in syphilis is associated with neuron-derived neurotrophic factor.
Mayo Clinic Laboratory and pathology research roundup: December 8 - Insights
This week’s research roundup features: The management of cancer symptoms and treatment-induced side effects with cannabis or cannabinoids.
Sleep Disorder Testing - Mayo Clinic Laboratories
Determining orexin-A/ hypocretin-1 levels through CSF testing provides a sensitive and specific result to guide appropriate treatment for patients.
Mayo Clinic Laboratories releases new, first-to-U.S.-market pregnancy risk assessment - Insights
Mayo Clinic Laboratories now offers the first preeclampsia-specific test (Mayo ID: PERA) that can be used to stratify patients into low or high-risk categories, indicating whether a patient is at risk for developing preeclampsia with severe...
Epic journey yields unique offering - Insights
The quest to create a test pinpointing the source of the rare, testicular cancer-associated illness successfully concluded in the summer of 2021.
Epansive clinical test menu, including more than 3,500 CAP- and CLIA-accredited tests. In addition to offering the world’s most sophisticated specialty test menu, we provide access to research-grade tests, pathology services, and sponsored...